• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种新型多基因检测板（Sig27）通过与免疫抑制特征的高度关联有力地预测肾细胞癌的不良预后。

A novel multigene panel (Sig27) robustly predicts poor prognosis of renal cell carcinoma via high-level associations with immunosuppressive features.

作者信息

Dong Ying, Shayegan Bobby, Su Yingying, Neira Sandra Vega, Tang Damu

机构信息

Urological Cancer Center for Research and Innovation (UCCRI), St Joseph's Hospital, Hamilton, ON, L8N 4A6, Canada.

Department of Surgery, McMaster University, Hamilton, ON, L8S 4K1, Canada.

出版信息

BJC Rep. 2025 Mar 17;3(1):16. doi: 10.1038/s44276-025-00128-3.

DOI:10.1038/s44276-025-00128-3
PMID:40097553
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11914224/
Abstract

BACKGROUND

We investigated a 27-gene panel (Sig27), derived from prostate cancer, for risk stratification of RCC (clear cell RCC/ccRCC, papillary RCC/pRCC, and chromophobe RCC/chRCC).

METHODS

Sig27 gene expressions were examined in 960 RCC and 201 kidney tissues. Sig27 was evaluated for predicting overall survival (OS), association with immune checkpoints (IC), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSC), and tumor-associated macrophages (TAM) in RCC.

RESULTS

Sig27 robustly predicts OS of ccRCC, pRCC, and chRCC. Sig27 stratifies high-risk ccRCCs: median survival month (MSM) 19.3 and 80.4% of deaths and high-risk pRCCs (MSM 19.6 and 58.6% of death) compared to low-risk ccRCCs (2.9% of death) and pRCCs (2.7% of fatality). Sig27 contains several novel genes related to the RCC immunosuppressive features. FPR3, NOD2, MCTP1, LAMP3, TFEC, and FAM65B are highly correlated with MDSC, Treg, TAM and multiple (≥12) ICs in RCCs. FPR3 and NOD2 are pattern recognition receptors and initiate proinflammatory responses via sensing pathogen-associated molecular patterns and damage-associated molecular patterns; their upregulations may contribute to chronic inflammation in RCC. The Sig27 metagene is expressed in ccRCC-associated immune cells: exhausted CD8T cells, TAM, Treg, and others.

CONCLUSIONS

Sig27 is a novel and effective pan-RCC biomarker with high-level associations with RCC immunosuppressive features.

摘要

背景

我们研究了一个源自前列腺癌的27基因panel（Sig27），用于肾细胞癌（透明细胞肾细胞癌/ccRCC、乳头状肾细胞癌/pRCC和嫌色性肾细胞癌/chRCC）的风险分层。

方法

检测了960例肾细胞癌和201例肾组织中Sig27基因的表达。评估Sig27在肾细胞癌中预测总生存期（OS）、与免疫检查点（IC）、调节性T细胞（Tregs）、髓源性抑制细胞（MDSC）和肿瘤相关巨噬细胞（TAM）的相关性。

结果

Sig27能可靠地预测ccRCC、pRCC和chRCC的OS。Sig27对高风险ccRCC进行分层：中位生存月数（MSM）为19.3，死亡占80.4%；高风险pRCC（MSM为19.6，死亡占58.6%），而低风险ccRCC（死亡占2.9%）和pRCC（死亡占2.7%）。Sig27包含几个与肾细胞癌免疫抑制特征相关的新基因。FPR3、NOD2、MCTP1、LAMP3、TFEC和FAM65B与肾细胞癌中的MDSC、Treg、TAM和多种（≥12种）IC高度相关。FPR3和NOD2是模式识别受体，通过感知病原体相关分子模式和损伤相关分子模式引发促炎反应；它们的上调可能导致肾细胞癌中的慢性炎症。Sig27元基因在ccRCC相关免疫细胞中表达：耗竭的CD8T细胞、TAM、Treg等。

结论

Sig27是一种新型有效的泛肾细胞癌生物标志物，与肾细胞癌免疫抑制特征高度相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/cf5d8c6da493/44276_2025_128_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/f8c589514d86/44276_2025_128_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/e68c2967b891/44276_2025_128_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/a3f9282fdd77/44276_2025_128_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/39b140333f2d/44276_2025_128_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/7d3a2edeb118/44276_2025_128_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/0ce259a8d711/44276_2025_128_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/af79c8a1e97e/44276_2025_128_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/cf5d8c6da493/44276_2025_128_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/f8c589514d86/44276_2025_128_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/e68c2967b891/44276_2025_128_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/a3f9282fdd77/44276_2025_128_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/39b140333f2d/44276_2025_128_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/7d3a2edeb118/44276_2025_128_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/0ce259a8d711/44276_2025_128_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/af79c8a1e97e/44276_2025_128_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a8d/11914224/cf5d8c6da493/44276_2025_128_Fig8_HTML.jpg

相似文献

1
A novel multigene panel (Sig27) robustly predicts poor prognosis of renal cell carcinoma via high-level associations with immunosuppressive features.一种新型多基因检测板（Sig27）通过与免疫抑制特征的高度关联有力地预测肾细胞癌的不良预后。
BJC Rep. 2025 Mar 17;3(1):16. doi: 10.1038/s44276-025-00128-3.
2
Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.I型和II型乳头状肾细胞癌（RCC）与透明细胞肾细胞癌的比较。
BJU Int. 2008 Nov;102(10):1381-4. doi: 10.1111/j.1464-410X.2008.07999.x. Epub 2008 Sep 8.
3
The Value of Contrast-Enhanced Ultrasound in Diagnosing Small Renal Cell Carcinoma Subtypes and Angiomyolipoma.超声造影在诊断小肾细胞癌亚型及肾血管平滑肌脂肪瘤中的价值
J Ultrasound Med. 2022 Jun;41(6):1415-1423. doi: 10.1002/jum.15824. Epub 2021 Sep 9.
4
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.一种新的分子特征可识别预后不良且对免疫治疗有独立反应的肾细胞癌混合亚型。
Genome Med. 2022 Sep 15;14(1):105. doi: 10.1186/s13073-022-01105-y.
5
Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.临床晚期乳头状和嫌色细胞肾细胞癌的临床病理和生存分析。
Urol Oncol. 2019 Oct;37(10):727-734. doi: 10.1016/j.urolonc.2019.05.008. Epub 2019 Jun 5.
6
The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.组织学亚型对肾细胞癌患者手术后复发的发生率、时间和模式的影响——来自 RECUR 联盟的结果。
Eur Urol Oncol. 2021 Jun;4(3):473-482. doi: 10.1016/j.euo.2020.09.005. Epub 2020 Oct 24.
7
Expression and clinical value of SALL4 in renal cell carcinomas.SALL4 在肾细胞癌中的表达及临床价值。
Mol Med Rep. 2020 Aug;22(2):819-827. doi: 10.3892/mmr.2020.11170. Epub 2020 May 22.
8
Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.Xp11.2 易位/TFE3 基因融合相关性成人肾细胞癌的超声造影表现：与透明细胞肾细胞癌和乳头状肾细胞癌的比较。
Cancer Imaging. 2019 Dec 31;20(1):1. doi: 10.1186/s40644-019-0268-7.
9
Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.肾细胞癌亚型中的代谢和脂质组学重编程反映了肿瘤起源区域。
Eur Urol Focus. 2019 Jul;5(4):608-618. doi: 10.1016/j.euf.2018.01.016. Epub 2018 Feb 13.
10
ARHGAP11A Is a Novel Prognostic and Predictive Biomarker Correlated with Immunosuppressive Microenvironment in Clear Cell Renal Cell Carcinoma.ARHGAP11A 是一种新型的预后和预测生物标志物，与透明细胞肾细胞癌中的免疫抑制微环境相关。
Int J Mol Sci. 2023 Apr 24;24(9):7755. doi: 10.3390/ijms24097755.

本文引用的文献

1
Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC.YM155 调节主要 RCC 亚型中一种表观遗传学酶的治疗效果。
Int J Mol Sci. 2023 Dec 22;25(1):216. doi: 10.3390/ijms25010216.
2
Chromophobe renal cell carcinoma.嫌色细胞性肾细胞癌。
Cancer Cell. 2023 Aug 14;41(8):1383-1388. doi: 10.1016/j.ccell.2023.07.006. Epub 2023 Aug 3.
3
PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.PI3K/AKT/mTOR 失调与肾癌代谢途径重编程：与 VHL/HIF 轴的串扰。
Int J Mol Sci. 2023 May 7;24(9):8391. doi: 10.3390/ijms24098391.
4
Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.目前透明细胞肾细胞癌中基因组生物标志物的研究现状。
Eur Urol. 2023 Aug;84(2):166-175. doi: 10.1016/j.eururo.2023.04.003. Epub 2023 Apr 19.
5
Formyl peptide receptor 2 is an emerging modulator of inflammation in the liver.甲酰肽受体 2 是肝脏炎症的一种新兴调节剂。
Exp Mol Med. 2023 Feb;55(2):325-332. doi: 10.1038/s12276-023-00941-1. Epub 2023 Feb 7.
6
MiT/TFE Family Renal Cell Carcinoma.MiT/TFE 家族肾细胞癌。
Genes (Basel). 2023 Jan 5;14(1):151. doi: 10.3390/genes14010151.
7
Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.靶向肿瘤重编程髓系细胞：癌症免疫治疗的新战场。
Semin Immunopathol. 2023 Mar;45(2):163-186. doi: 10.1007/s00281-022-00965-1. Epub 2022 Sep 26.
8
Role of RHO family interacting cell polarization regulators (RIPORs) in health and disease: Recent advances and prospects.RHO 家族相互作用的细胞极化调节因子（RIPORs）在健康和疾病中的作用：最新进展和前景。
Int J Biol Sci. 2022 Jan 1;18(2):800-808. doi: 10.7150/ijbs.65457. eCollection 2022.
9
Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome.乳头状肾细胞癌：单机构 199 例研究分析其分类、临床病理和分子特征以及治疗结果。
Mod Pathol. 2022 Jun;35(6):825-835. doi: 10.1038/s41379-021-00990-9. Epub 2021 Dec 23.
10
Renal Cell Carcinoma in Tuberous Sclerosis Complex.结节性硬化症相关肾细胞癌。
Genes (Basel). 2021 Oct 8;12(10):1585. doi: 10.3390/genes12101585.